We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a surprise move based on public outcry, Gilead asked the FDA to rescind remdesivir’s orphan drug designation as a potential COVID-19 treatment. Read More
Eli Lilly and Boehringer Ingelheim received a complete response letter from the FDA for their supplemental NDA for Jardiance (empagliflozin) 2.5mg as an adjunct to insulin for adults with type 1 diabetes. Read More